Clinical trial NCT03017508 - References

Social Anxiety Disorder — Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder

Citation(s)

•   Baker SL, Heinrichs N, Kim HJ, Hofmann SG
  The liebowitz social anxiety scale as a self-report instrument: a preliminary psychometric analysis. Behav Res Ther. 2002 Jun;40(6):701-15.
•   Davidson JR
  Use of benzodiazepines in social anxiety disorder, generalized anxiety disorder, and posttraumatic stress disorder. J Clin Psychiatry. 2004;65 Suppl 5:29-33. Review.
•   Mathew SJ, Amiel JM, Coplan JD, Fitterling HA, Sackeim HA, Gorman JM
  Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry. 2005 Dec;162(12):2379-81.
•   Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G
  Riluzole in the treatment of mood and anxiety disorders. CNS Drugs. 2008;22(9):761-86. Review.
•   Ries BJ, McNeil DW, Boone ML, Turk CL, Carter LE, Heimberg RG
  Assessment of contemporary social phobia verbal report instruments. Behav Res Ther. 1998 Oct;36(10):983-94.
•   Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, Krystal JH
  Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry. 2007 Mar 15;61(6):822-5. Epub 2006 Dec 4.

Double-Blind, Placebo-Controlled, Single-Dose Crossover Study Examining the Effects of Sublingual Riluzole (BHV-0223) on Public Speaking in Social Anxiety Disorder

Details for clinical trial NCT03017508